Plasma levels of soluble CD105 correlate with metastasis in patients with breast cancer.

2.50
Hdl Handle:
http://hdl.handle.net/10541/86509
Title:
Plasma levels of soluble CD105 correlate with metastasis in patients with breast cancer.
Authors:
Li, Chenggang; Guo, Baoqiang; Wilson, Philip B; Stewart, Alan L; Byrne, Ged J; Bundred, Nigel J; Kumar, Shant
Abstract:
CD105 (endoglin), a receptor for transforming growth factor (TGF) beta1 and beta3 in vascular endothelial cells, is highly up-regulated in blood vessels of tissues where neovascularisation occurs. It modulates endothelial-mesenchymal signalling and is essential for angiogenesis. Indeed, CD105 knock-out mice die from malvascularisation by 11.5 day p.c. In the present study CD105, TGFbeta1 and CD105/TGFbeta1 complexes were quantified in plasma samples from 77 healthy individuals and 92 patients with early stage breast cancer prior to any treatment. When compared with normal controls, both CD105 and CD105/TGFbeta1 complex levels were significantly elevated in breast cancer patients, whereas TGFbeta1 levels were lower in cancer patients. The most important finding to emerge was that CD105 levels were significantly increased in patients who developed distant metastasis compared with disease-free patients. While there was no significant difference between CD105 levels in controls compared to disease-free patients, it was significantly higher in patients with metastatic disease. Thus patients who had died following local relapse or distant metastases possessed the highest levels of CD105. Neither CD105/TGFbeta1 complex nor TGFbeta1 levels correlated with tumour progression. Our data indicate that CD105 might be a valuable novel angiogenic marker for identifying breast cancer patients who are at high risk of developing metastasis.
Affiliation:
Department of Pathological Sciences, Medical School, University of Manchester, UK.
Citation:
Plasma levels of soluble CD105 correlate with metastasis in patients with breast cancer. 2000, 89 (2):122-6 Int. J. Cancer
Journal:
International Journal of Cancer
Issue Date:
20-Mar-2000
URI:
http://hdl.handle.net/10541/86509
DOI:
10.1002/(SICI)1097-0215(20000320)89:2<122::AID-IJC4>3.0.CO;2-M
PubMed ID:
10754488
Type:
Article
Language:
en
ISSN:
0020-7136
Appears in Collections:
All Christie Publications

Full metadata record

DC FieldValue Language
dc.contributor.authorLi, Chenggangen
dc.contributor.authorGuo, Baoqiangen
dc.contributor.authorWilson, Philip Ben
dc.contributor.authorStewart, Alan Len
dc.contributor.authorByrne, Ged Jen
dc.contributor.authorBundred, Nigel Jen
dc.contributor.authorKumar, Shanten
dc.date.accessioned2009-11-19T16:15:49Z-
dc.date.available2009-11-19T16:15:49Z-
dc.date.issued2000-03-20-
dc.identifier.citationPlasma levels of soluble CD105 correlate with metastasis in patients with breast cancer. 2000, 89 (2):122-6 Int. J. Canceren
dc.identifier.issn0020-7136-
dc.identifier.pmid10754488-
dc.identifier.doi10.1002/(SICI)1097-0215(20000320)89:2<122::AID-IJC4>3.0.CO;2-M-
dc.identifier.urihttp://hdl.handle.net/10541/86509-
dc.description.abstractCD105 (endoglin), a receptor for transforming growth factor (TGF) beta1 and beta3 in vascular endothelial cells, is highly up-regulated in blood vessels of tissues where neovascularisation occurs. It modulates endothelial-mesenchymal signalling and is essential for angiogenesis. Indeed, CD105 knock-out mice die from malvascularisation by 11.5 day p.c. In the present study CD105, TGFbeta1 and CD105/TGFbeta1 complexes were quantified in plasma samples from 77 healthy individuals and 92 patients with early stage breast cancer prior to any treatment. When compared with normal controls, both CD105 and CD105/TGFbeta1 complex levels were significantly elevated in breast cancer patients, whereas TGFbeta1 levels were lower in cancer patients. The most important finding to emerge was that CD105 levels were significantly increased in patients who developed distant metastasis compared with disease-free patients. While there was no significant difference between CD105 levels in controls compared to disease-free patients, it was significantly higher in patients with metastatic disease. Thus patients who had died following local relapse or distant metastases possessed the highest levels of CD105. Neither CD105/TGFbeta1 complex nor TGFbeta1 levels correlated with tumour progression. Our data indicate that CD105 might be a valuable novel angiogenic marker for identifying breast cancer patients who are at high risk of developing metastasis.en
dc.language.isoenen
dc.subjectBreast Canceren
dc.subjectCancer Stagingen
dc.subject.meshAdult-
dc.subject.meshAntigens, CD-
dc.subject.meshBreast Neoplasms-
dc.subject.meshCase-Control Studies-
dc.subject.meshEnzyme-Linked Immunosorbent Assay-
dc.subject.meshFemale-
dc.subject.meshHumans-
dc.subject.meshLymphatic Metastasis-
dc.subject.meshMiddle Aged-
dc.subject.meshNeoplasm Staging-
dc.subject.meshReceptors, Cell Surface-
dc.subject.meshTransforming Growth Factor beta-
dc.subject.meshVascular Cell Adhesion Molecule-1-
dc.titlePlasma levels of soluble CD105 correlate with metastasis in patients with breast cancer.en
dc.typeArticleen
dc.contributor.departmentDepartment of Pathological Sciences, Medical School, University of Manchester, UK.en
dc.identifier.journalInternational Journal of Canceren

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.